BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
토요일, 9월 26

Mineralys Therapeutics Inc

MLYSNASDAQ
Trade with Public
Trade with Public
$25.86
-0.73-2.75%
가까이에: Sep 25, 5:00 PM EST
$25.86
N/A
시간외: 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Mineralys Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mineralys Therapeutics (MLYS).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$49Upside to Avg. PT+88.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Apr 27, 2026TD CowenTara BancroftInitiateBuy—
Mar 13, 2026B of A SecuritiesGreg HarrisonPT RaiseBuy$46→$51
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

TD Cowen analyst Tara Bancroft initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $42 to $52.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved